Match your tumor test to a targeted cancer drug
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older, with advanced cancer that has spread (and it cannot be a primary brain tumor).
- There is no proven standard treatment that can prolong life, or you chose not to take it; ECOG stamina score is 0–2.
- Your blood counts and organ function are strong enough (examples: platelets and white blood cells are above required levels, and liver/kidney tests are within limits).
- Your cancer is measurable on scans, and your tumor has test results showing a potentially actionable genetic or protein change.
- You can travel to and receive care at a participating center for treatment and follow-up (for example, within about 1.5 hours driving).
- If you could become pregnant, you agree to use very effective birth control; you must be willing to sign consent for screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.